Dutasteride vs RU-58841
FDA Approved vs Limited Research
synergistic Similar rationale to the finasteride combination. Dutasteride inhibits both Type I and Type II 5-alpha reductase isoforms, providing more aggressive DHT suppression than finasteride. Adding RU-58841 blocks any remaining androgens at the receptor. This is considered an aggressive combination and is typically reserved for advanced hair loss.
Molecular Data
Dutasteride RU-58841
Weight 528.53 Da 369.34 Da
Half-life ~5 weeks (extremely long; active metabolite accumulation over months) ~1 hour topically (very short systemic half-life)
Type Synthetic 4-azasteroid compound (dual 5-alpha reductase inhibitor) Non-steroidal anti-androgen
Key Benefits
Dutasteride
01 Inhibits both Type I and Type II 5-alpha reductase for more complete DHT suppression
02 Reduces serum DHT by approximately 90%, compared to 70% with finasteride
03 Head-to-head trials show superior hair count improvements over finasteride at 12 and 24 weeks
04 FDA-approved for BPH with well-established long-term safety data
05 Extremely long half-life allows for flexible dosing schedules (daily or 3x per week)
06 Convenient once-daily oral dosing with no injections required
07 Can be combined with minoxidil for enhanced hair loss treatment
RU-58841
01 Blocks DHT directly at the androgen receptor in hair follicles without reducing systemic DHT levels
02 Extremely short systemic half-life limits risk of systemic anti-androgenic side effects
03 Different mechanism of action from finasteride/dutasteride, allowing combination therapy
04 Animal studies demonstrated significant hair regrowth in androgen-dependent alopecia models
05 Topical application targets the site of action directly
06 Does not interfere with systemic testosterone or DHT levels
Side Effects
Dutasteride
Decreased libido (reported in 3-5% of men; somewhat higher incidence than finasteride due to greater DHT suppression)
Erectile dysfunction (reported in 3-5%; more frequently reported than with finasteride)
Decreased ejaculate volume (reported in 1-2%)
Gynecomastia or breast tenderness (reported in approximately 1-2%)
RU-58841
Scalp irritation, dryness, or itching at the application site (often related to the vehicle/solvent rather than RU-58841 itself)
Contact dermatitis in sensitive individuals
Scalp flaking or peeling
Contraindications
Women who are pregnant or may become pregnant (dutasteride is teratogenic and can cause abnormalities of external genitalia in a male fetus; even handling damaged capsules poses a risk due to skin absorption)
Women who are breastfeeding
Known hypersensitivity to dutasteride, other 5-alpha reductase inhibitors, or any component of the formulation
Severe hepatic impairment (dutasteride is extensively metabolized by the liver via CYP3A4)
Pediatric patients (not indicated for use in children)
Co-administration with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) may significantly increase dutasteride levels
Women who are pregnant or may become pregnant (anti-androgens can cause feminization of a male fetus)
Women who are breastfeeding
Known hypersensitivity to RU-58841 or related non-steroidal anti-androgens
Active scalp infections, open wounds, or severely compromised skin barrier on the scalp
Individuals taking systemic anti-androgens (risk of additive anti-androgenic effects)
Research Evidence
Dutasteride RU-58841
Status FDA Approved Limited Research
References 5 studies 4 studies
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.